Related references
Note: Only part of the references are listed.PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
Tianrui Yang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
Brain malignancies: Glioblastoma and brain metastases
Tamara T. Lah et al.
SEMINARS IN CANCER BIOLOGY (2020)
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma
Patrick Y. Wen et al.
CLINICAL CANCER RESEARCH (2020)
The increased IL-17-producing γδT cells promote tumor cell proliferation and migration in neuroblastoma
Hui Zhang et al.
CLINICAL IMMUNOLOGY (2020)
Treating Brain Metastases from Breast Cancer: Outcomes after Stereotactic Radiosurgery
T. G. Wilson et al.
CLINICAL ONCOLOGY (2020)
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
Mustafa Khasraw et al.
CLINICAL CANCER RESEARCH (2020)
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Xin Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
The IL-17 Family of Cytokines in Health and Disease
Mandy J. McGeachy et al.
IMMUNITY (2019)
PD-L1/PD-1 Axis in Glioblastoma Multiforme
Jakub Litak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)
John D. Hainsworth et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
IL-17 induces the proliferation and migration of glioma cells through the activation of PI3K/Akt1/NF-κB-p65
Bin Wang et al.
CANCER LETTERS (2019)
IL-17A promotes cell migration and invasion of glioblastoma cells via activation of PI3K/AKT signalling pathway
Qianqian Zheng et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Brain metastases
Achal Singh Achrol et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Menthol-modified casein nanoparticles loading 10-hydroxycamptothecin for glioma targeting therapy
Caifang Gao et al.
ACTA PHARMACEUTICA SINICA B (2019)
Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment
Songwen Lin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
Wennan Zhao et al.
ACTA PHARMACEUTICA SINICA B (2017)
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer
Qin Zhou et al.
BIOCHEMICAL PHARMACOLOGY (2016)
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Xiaoman Li et al.
ONCOTARGET (2016)
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma
Laurent Salphati et al.
DRUG METABOLISM AND DISPOSITION (2016)
FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
Barry W. Miller et al.
CLINICAL CANCER RESEARCH (2015)
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2015)
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Lauren M. Thorpe et al.
NATURE REVIEWS CANCER (2015)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos et al.
CLINICAL CANCER RESEARCH (2014)
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
Seth A. Wander et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding
Arshawn Sami et al.
TUMOR BIOLOGY (2013)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Shile Huang et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2012)
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
Gautam Prasad et al.
NEURO-ONCOLOGY (2011)
Brain metastases
April F. Eichler et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
The interplay of cell-cell and cell-matrix interactions in the invasive properties of brain tumors
Balazs Hegedus et al.
BIOPHYSICAL JOURNAL (2006)
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
M Cully et al.
NATURE REVIEWS CANCER (2006)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Mutant PIK3CA promotes cell growth and invasion of human cancer cells
Y Samuels et al.
CANCER CELL (2005)
PI3K/Akt signalling pathway and cancer
JAF Vara et al.
CANCER TREATMENT REVIEWS (2004)
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells
N Gao et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2004)
Oncogenic mutations of PIK3CA in human cancers
Y Samuels et al.
CELL CYCLE (2004)
Share Paper
